ArticleWorld journal of gastroenterology2001
Inhibition of hepatitis B virus by oxymatrine in vivo.
Article in World journal of gastroenterology, 2001. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 2 syntheses or guidelines pooled it, 65 citations in OpenAlex.
- Oxymatrine for inflammatory bowel disease in preclinical studies: a systematic review and meta-analysis.Frontiers in medicine · 2025Pooled it
- Oral oxymatrine preparation for chronic hepatitis B: A systematic review of randomized controlled trials.Chinese journal of integrative medicine · 2016Pooled it
- Oxymatrine therapy for chronic hepatitis B: a randomized double-blind and placebo-controlled multi-center trial.World journal of gastroenterology · 2003Trial
- Oxymatrine Modulation of TLR3 Signaling: A Dual-Action Mechanism for H9N2 Avian Influenza Virus Defense and Immune Regulation.Molecules (Basel, Switzerland) · 2024Article
- Metabolites from traditional Chinese botanical drugs with anti-hepatitis B virus activity - a review.Frontiers in pharmacology · 2024Review
- Anti-Alphaviral Alkaloids: Focus on Some Isoquinolines, Indoles and Quinolizidines.Molecules (Basel, Switzerland) · 2022Review
- Effect of oxymatrine on liver gluconeogenesis is associated with the regulation of PEPCK and G6Pase expression and AKT phosphorylation.Biomedical reports · 2021Article
- Kushenol C Prevents Tert-Butyl Hydroperoxide and Acetaminophen-Induced Liver Injury.Molecules (Basel, Switzerland) · 2021Article
- Oxymatrine protects against l-arginine-induced acute pancreatitis and intestine injury involving Th1/Th17 cytokines and MAPK/NF-κB signalling.Pharmaceutical biology · 2019Article
- Prevalence and current therapy in chronic liver disorders.Inflammopharmacology · 2019Review
- Sophoraflavenone G Restricts Dengue and Zika Virus Infection via RNA Polymerase Interference.Viruses · 2017Article
- T cell--associated immunoregulation and antiviral effect of oxymatrine in hydrodynamic injection HBV mouse model.Acta pharmaceutica Sinica. B · 2017Article
- Pharmacological Intervention in Hepatic Stellate Cell Activation and Hepatic Fibrosis.Frontiers in pharmacology · 2016Review
- Anti-HBV Drugs: Progress, Unmet Needs, and New Hope.Viruses · 2015Review
- Nanotechnology applications for the therapy of liver fibrosis.World journal of gastroenterology · 2014Review
- Oxymatrine triggers apoptosis by regulating Bcl-2 family proteins and activating caspase-3/caspase-9 pathway in human leukemia HL-60 cells.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2014Article
- Management of chronic hepatitis B infection: current treatment guidelines, challenges, and new developments.World journal of gastroenterology · 2014Review
- Protective effects of the combination of sodium ferulate and oxymatrine on cecal ligation and puncture-induced sepsis in mice.Experimental and therapeutic medicine · 2014Article
- Complementary and alternative medications in hepatitis C infection.World journal of hepatology · 2014Review
- Anti-inflammatory Effects of Oxymatrine Through Inhibition of Nuclear Factor-kappa B and Mitogen-activated Protein Kinase Activation in Lipopolysaccharide-induced BV2 Microglia Cells.Iranian journal of pharmaceutical research : IJPR · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimTo investigate the anti-HBV effect of oxymatrine (oxy) in vivo.
methodsHBV transgenic mice were produced by micro-injection of a 4.2 kb fragment containing the complete HBV genomes. Expression level of HBsAg and HBcAg in the transgenic mice liver was determined by immunohistochemical assay.
resultsFour groups (6 mice in each group) were injected intraperitoneally with oxy at the dosage of 100, 200, and 300 mg/kg or with saline once a day for 30 days. Both HBsAg and HBcAg were positive in livers of all the six mice in the control group (injected with saline), and were positive in livers of two mice in 100mg/kg group and 300 mg/kg group. In 200 mg/kg group, HBsAg and HBcAg were negative in livers of all the six mice. Based on the results, 200mg/kg is the ideal dosage to explore the effect of oxy at different time points. According to the oxy treatment time, mice were divided into four groups: 10 d, 20 d, 30 d and 60 d (4 mice in each group). Each mouse underwent liver biopsy two weeks before the treatment of oxy. Down-regulation of HBsAg and HBcAg appeared after treatment of oxymatrine for 10 d and 20 d, Dane-like particles disappeared after the treatment of oxy for 20 d under electron microscopy, however, the expression level of HBsAg and HBcAg returned to normal 60 d later after oxy treatment.
conclusionOxymatrine can reduce the contents of HBsAg and HBcAg in transgenic mice liver,longer treatment time and larger dosage do not yield better effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.